Dividendos de UCB

Dividendo controles de criterios 0/6

UCB es una empresa que paga dividendos con una rentabilidad actual de 1.09%.

Información clave

1.1%

Rentabilidad por dividendo

75%

Ratio de pago

Rentabilidad media de la industria	2.3%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	€1.81
Rentabilidad por dividendo prevista a 3 años	1.1%

Últimas actualizaciones de dividendos

Recent updates

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Apr 19

Is UCB (EBR:UCB) A Risky Investment?

Mar 27

Earnings Tell The Story For UCB SA (EBR:UCB) As Its Stock Soars 26%

Mar 04

UCB SA's (EBR:UCB) P/E Is On The Mark

Dec 28

UCB (EBR:UCB) Takes On Some Risk With Its Use Of Debt

Nov 12

Is UCB (EBR:UCB) Using Too Much Debt?

Aug 07

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Jun 02

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Apr 05

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Apr 03

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

Dec 05

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Sep 05

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Jun 06

UCB (EBR:UCB) Is Paying Out A Larger Dividend Than Last Year

Apr 23

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Apr 09

UCB (EBR:UCB) Has Announced That It Will Be Increasing Its Dividend To €0.91

Mar 26

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

Dec 23

Are Investors Undervaluing UCB SA (EBR:UCB) By 42%?

Dec 05

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

Sep 23

UCB SA (EBR:UCB) Shares Could Be 44% Below Their Intrinsic Value Estimate

Sep 05

UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Jul 31

Is UCB (EBR:UCB) A Risky Investment?

Jun 21

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 96% Above Its Share Price

May 13

Is UCB (EBR:UCB) Using Too Much Debt?

Mar 18

Will Weakness in UCB SA's (EBR:UCB) Stock Prove Temporary Given Strong Fundamentals?

Feb 28

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 54% Above Its Share Price

Feb 10

What Makes UCB SA (EBR:UCB) A Great Dividend Stock?

Jan 20

Is UCB SA (EBR:UCB) Popular Amongst Institutions?

Jan 07

UCB (EBR:UCB) Is Growing Earnings But Are They A Good Guide?

Dec 23

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: UCB no paga un dividendo notable para el mercado Belgian, por lo que no es necesario comprobar si los pagos son estables.

Dividendo creciente: UCB no paga un dividendo notable para el mercado Belgian, por lo que no es necesario comprobar si los pagos aumentan.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de UCB vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de UCB con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (UCB)	1.1%
Suelo de mercado 25% (BE)	1.9%
Techo de mercado 25% (BE)	6.8%
Media de la industria (Pharmaceuticals)	2.3%
Previsión de analistas en 3 años (UCB)	1.1%

Dividendo destacado: El dividendo de UCB(1.09%) no es notable en comparación con el 25% inferior de pagadores de dividendos del mercado Belgian (2.06%).

Alto dividendo: El (1.09%) del dividendo de UCB es bajo en comparación con el 25% de los principales pagadores de dividendos del mercado Belgian (6.88%).

Pago de beneficios a los accionistas

Cobertura de los beneficios: UCB no paga un dividendo notable para el mercado Belgian.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: UCB no paga un dividendo notable para el mercado Belgian.

Dividendos de UCB

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Upcoming dividend of €0.93 per share at 1.5% yield

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

UCB (EBR:UCB) Is Paying Out A Larger Dividend Than Last Year

Upcoming dividend of €0.91 per share

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

UCB (EBR:UCB) Has Announced That It Will Be Increasing Its Dividend To €0.91

Recent updates

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB SA to Report First Half, 2024 Results on Jul 25, 2024

Dividend of €0.95 announced

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Consensus EPS estimates increase by 18%

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

Is UCB (EBR:UCB) A Risky Investment?

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

Price target increased by 9.4% to €111

Consensus EPS estimates fall by 14%

Earnings Tell The Story For UCB SA (EBR:UCB) As Its Stock Soars 26%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB SA's (EBR:UCB) P/E Is On The Mark

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB (EBR:UCB) Takes On Some Risk With Its Use Of Debt

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Is UCB (EBR:UCB) Using Too Much Debt?

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022)

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Upcoming dividend of €0.93 per share at 1.5% yield

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 16%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

First half 2022 earnings released

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB (EBR:UCB) Is Paying Out A Larger Dividend Than Last Year

Upcoming dividend of €0.91 per share

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB (EBR:UCB) Has Announced That It Will Be Increasing Its Dividend To €0.91

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results

UCB Announces Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

UCB SA Announces Positive Top-Line Interim Analysis Results Showing That the Phase 3 Be Mobile 1 Study Met the Primary and All Ranked Secondary Endpoints

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

UCB SA Announces Positive Top-Line Interim Analysis Results from the Phase 3 Be Mobile 2 Study